Meta-analysis: Pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 4, 2010, Pages 486-492

  Yang, Z ^a   Wu, Q ^a   Wu, K ^a   Fan, D ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ABSCESS; ARTICLE; CLINICAL TRIAL; COLON RESECTION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTIOUS COMPLICATION; INTESTINE OBSTRUCTION; MEDLINE; META ANALYSIS; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SEPSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; ULCERATIVE COLITIS; WOUND INFECTION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CONTROL GROUPS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROCTOCOLECTOMY, RESTORATIVE; PUBMED; SURGICAL WOUND INFECTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 74049087382     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04204.x     Document Type: Article

References (28)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007 369 : 1641 1657.
2. Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2009 3 : 395 405.
3. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999 28 : 255 281.
4. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2008 44 : 431 440.
5. Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008 2 : 357 370.
6. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 347 : 417 429.
7. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008 28 : 674 688.
8. Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol 2009 3 : 219 229.
9. Brzezinski A, Armstrong L, Alvarez Del Real G, et al. Infliximab does not increase the risk of complications in the pre-operative period in patients with Crohn's disease. Gastroenterology 2002 122 : A617.
10. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004 19 : 749 754.
11. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004 99 : 878 883.
12. Jones DT, Osterman MT, Bewtra M, et al. Passive smoking and inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008 103 : 2382 2393.
13. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000 283 : 2008 2012.
14. Subramanian V, Pollok RC, Kang JY, et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Brit J Surg 2006 93 : 793 799.
15. Shen B. Impact of pre-operative infliximab use on postoperative infectious complications in ulcerative colitis: the price we have to pay? Inflamm Bowel Dis 2008 14 : 1019 1021.
16. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007 26 : 747 756.
17. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007 25 : 1055 1060.
18. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007 204 : 956 962.
19. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007 50 : 1747 1753.
20. Mor IJ, Vogel JD, da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008 51 : 1202 1207.
21. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008 12 : 1730 1736.
22. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009 15 : 1062 1070.
23. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128 : 1805 1811.
24. Halfvarson J, Jarnerot G. Treatment of choice for acute severe steroid-refractory ulcerative colitis is remicade. Inflamm Bowel Dis 2009 15 : 143 145.
25. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006 4 : 621 630.
26. D'Haens G, Colombel JF, Hommes DW, et al. Corticosteroids pose an increased risk for serious infection: an interim safety analysis of the ENCORE registry. Gastroenterology 2008 134 : A140.
27. Subramanian V, Saxena S, Kang JY, et al. Pre-operative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008 103 : 2373 2381.
28. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001 15 : 463 473.